Brussels, Belgium – 1 April 2025 – 7AM CET –

比利时布鲁塞尔——2025年4月1日——欧洲中部时间早上7点——

UCB, a global biopharmaceutical company, today announced it will present 8 scientific abstracts, including 3 late-breaker oral presentations, highlighting key data from its innovative neurodegeneration research programs in Parkinson’s and Alzheimer’s disease, at this year’s AD/PD 2025 meeting, Vienna, Austria, April 1-4, 2025..

优时比（UCB），一家全球生物制药公司，今日宣布将在2025年4月1日至4日于奥地利维也纳举行的2025年阿尔茨海默病和帕金森病国际会议（AD/PD 2025）上展示8项科学摘要，其中包括3场最新突破性口头报告，重点介绍其在帕金森病和阿尔茨海默病神经退行性研究领域的关键数据。

'We are excited to present data on many aspects of our science and patient-driven neurodegeneration research program at AD/PD, highlighting promising insights into the underlying mechanisms of Alzheimer’s and Parkinson’s disease. The findings represent an important step forward in our efforts to develop effective treatments, bringing us closer to addressing these devastating neurodegenerative conditions,” said Alistair Henry, Chief Scientific Officer, UCB..

“我们很高兴在AD/PD会议上展示我们科学和以患者为中心的神经退行性疾病研究项目的多个方面数据，揭示了阿尔茨海默病和帕金森病潜在机制的有希望的见解。这些发现代表了我们在开发有效治疗方法的重要一步，使我们更接近于应对这些破坏性的神经退行性疾病，”UCB首席科学官阿里斯泰尔·亨利表示。

In Alzheimer’s disease, topline results from the TOGETHER phase 2a trial of bepranemab were released in October 2024 - the first study to provide evidence for clinical efficacy of anti-tau therapy in Alzheimer’s disease2 – and a subgroup analysis of this data is presented at AD/PD.

2024年10月，阿尔茨海默病TOGETHER 2a期试验中贝普奈单抗的顶线结果发布——这是首个证明抗tau疗法在阿尔茨海默病中临床疗效的研究——并在AD/PD会议上展示了该数据的亚组分析。

1

1

In Parkinson’s disease, UCB’s research program includes investigating mechanisms to inhibit the misfolding and propagation of alpha-synuclein - processes believed to underlie the spread of neurodegeneration. Alongside this, the company is advancing research into new therapies for symptom control, recognizing the diverse needs of each patient throughout their disease trajectory.

在帕金森病领域，优时比（UCB）的研究项目包括探索抑制α-突触核蛋白错误折叠和传播的机制——这些过程被认为是神经退行性病变扩散的基础。与此同时，公司正在推进针对症状控制的新疗法研究，认识到每位患者在疾病过程中多样化的需求。

Assets include UCB7853, currently under investigation for preventing extracellular alpha-synuclein spread, and glovadalen (UCB0022), an orally available, brain-penetrant, small molecule, designed to enhance the potency of dopamine ‘when and where needed’ to activate the dopamine D1 receptor and thereby improve symptom control..

资产包括UCB7853，目前正在进行防止细胞外α-突触核蛋白扩散的研究，以及口服可用、可穿透大脑的小分子药物格洛瓦达伦（UCB0022），它旨在“在需要时和需要的地方”增强多巴胺的效力，以激活多巴胺D1受体，从而改善症状控制。

6,7

6,7

Data at AD/PD include results from ORCHESTRA, a phase II proof-of-concept study assessing the efficacy and safety of minzasolmin in people with early-stage Parkinson’s disease.

AD/PD会议上的数据包括ORCHESTRA研究的结果，这是一项评估米那佐尔明在早期帕金森病患者中疗效和安全性的II期概念验证研究。

8

8

UCB previously announced this study did not meet its primary or secondary clinical endpoints.

UCB此前宣布，这项研究未达到其主要或次要临床终点。

9

9

Data presentations at AD/PD

AD/PD上的数据展示

Alzheimer’s disease

阿尔茨海默病

Barton M, et al. Phase II study of bepranemab in people with prodromal-mild Alzheimer’s disease: Population subgroup analysis. (Late-breaker oral presentation)

巴顿·M 等。贝普那单抗治疗前驱期至轻度阿尔茨海默病患者的二期研究：人群亚组分析。（最新突破性口头报告）

Byrnes W, et al. Safety MRI and volumetric MRI results from TOGETHER, a double-blind, placebo-controlled phase II study of bepranemab in prodromal-mild Alzheimer’s disease. (Late-breaker oral presentation)

Byrnes W 等。TOGETHER 研究的安全性 MRI 和体积 MRI 结果，这是一项关于贝普拉奈单抗在前驱期至轻度阿尔茨海默病中的双盲、安慰剂对照 II 期研究。（最新突破性口头报告）

Parkinson’s disease

帕金森病

Carson S, et al. Results from ORCHESTRA, a phase II proof-of-concept study assessing the efficacy and safety of minzasolmin in people with early-stage Parkinson’s disease. (Late-breaker oral presentation)

卡森 S 等人。ORCHESTRA 二期概念验证研究的结果，评估米扎索尔明在早期帕金森病患者中的疗效和安全性。（最新突破性口头报告）

Downey P, et al. A preclinical evaluation of UCB7853, an anti-alpha-synuclein antibody in clinical development for Parkinson’s disease. (Poster presentation)

Downey P 等。UCB7853 的临床前评估，这是一种正在临床开发中的针对帕金森病的抗 α-突触核蛋白抗体。（海报展示）

Kremer P, et al. Phase I study results: UCB7853 safety, tolerability and pharmacokinetics in healthy participants (single-ascending dose) and people with Parkinson’s disease (multiple-ascending doses). (Poster presentation)

Kremer P, 等。一期研究结果：UCB7853 在健康参与者（单次递增剂量）和帕金森病患者（多次递增剂量）中的安全性、耐受性和药代动力学。（海报展示）

Biagioni M, et al. Designing a patient-informed trial: ATLANTIS Phase II study of the D1 receptor PAM, UCB0022, in advanced Parkinson’s disease. (Poster presentation)

比阿吉奥尼 M 等。设计以患者为中心的试验：UCB0022（D1受体PAM）在晚期帕金森病中的ATLANTIS二期研究。（海报展示）

Morel T, et al. First qualitative assessment of the clinical meaningfulness of MDS-UPDRS Part III in early-stage Parkinson’s disease. (Poster presentation)

Morel T 等。MDS-UPDRS 第 III 部分在早期帕金森病中的临床意义的首次定性评估。（海报展示）

Williamson N, et al. Qualitative patient experience of advanced Parkinson’s disease: A conceptual model of symptoms and health-related quality of life impacts. (Poster presentation)

威廉姆森 N 等。晚期帕金森病患者的定性体验：症状与健康相关生活质量影响的概念模型。（海报展示）

The safety and efficacy of bepranemab, minzasolmin, glovadalen, and UCB7853 have not been established, and they are not currently approved for use in this indication by any regulatory authority worldwide.

贝普拉单抗、明扎索尔明、格洛瓦达伦和UCB7853的安全性和有效性尚未确定，目前全球任何监管机构均未批准它们用于此适应症。

For further information, contact UCB:

如需更多信息，请联系UCB：

Global Communications

全球通讯

Nick Francis

尼克·弗朗西斯

T: +44 7769 307745

电话：+44 7769 307745

nick.francis@ucb.com

nick.francis@ucb.com

Global Corporate Communications

全球企业传播

Laurent Schots

劳伦特·肖茨

T: +32.2.559.92.64

电话：+32.2.559.92.64

laurent.schots@ucb.com

laurent.schots@ucb.com

Investor Relations

投资者关系

Antje Witte

安特耶·维特

T: +32.2.559.94.14

电话：+32.2.559.94.14

antje.witte@ucb.com

antje.witte@ucb.com

About UCB

关于UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9000 people in approximately 40 countries, the company generated revenue of € 6.1 billion in 2024.

优时比公司（UCB），位于比利时布鲁塞尔（www.ucb.com），是一家全球生物制药公司，专注于发现和开发创新药物与解决方案，以改变免疫系统或中枢神经系统严重疾病患者的生活。该公司在约40个国家拥有9000多名员工，并在2024年实现了61亿欧元的收入。

UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.

UCB在布鲁塞尔泛欧交易所上市（股票代码：UCB）。请在Twitter上关注我们：@UCB_news。

Forward looking statements

前瞻性声明

This press release may contain forward-looking statements including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management.

本新闻稿可能包含前瞻性陈述，包括但不限于包含“相信”、“预期”、“预计”、“打算”、“计划”、“寻求”、“估计”、“可能”、“将”、“继续”等词语的陈述。这些前瞻性陈述基于管理层当前的计划、估计和信念。

All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results.

所有声明，除历史事实声明外，均可能被视为前瞻性声明，包括收入、营业利润率、资本支出、现金、其他财务信息、预期法律、仲裁、政治、监管或临床结果或实践以及其他此类估计和结果。

By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to differ materially from those that may be expressed or implied by such forward-looking statements contained in this press release.

由于此类前瞻性陈述的性质，其并非未来业绩的保证，并且受已知和未知风险、不确定性及假设的影响，这些因素可能导致UCB的实际结果、财务状况、表现或成就，或行业结果，与本新闻稿中包含的此类前瞻性陈述所表达或暗示的结果存在重大差异。

Important factors that could result in such differences include: the global spread and impact of COVID-19, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability .

可能导致此类差异的重要因素包括：新冠疫情的全球传播和影响、宏观经济、商业和竞争环境的变化、无法获得必要的监管批准或在可接受的条件及预期时间内获得这些批准、与研发相关的成本、UCB产品管线或正在开发中的产品前景变化、未来司法裁决或政府调查的影响、安全性、质量、数据完整性或生产问题；潜在或实际的数据安全和隐私泄露，或我们的信息技术系统中断、产品责任。

Given these uncertainties, you should not place undue reliance on any of such forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labelling in any market, or at any particular time, nor can there be any guarantee that such products will be or will continue to be commercially successful in the future. .

鉴于这些不确定性，您不应过分依赖任何此类前瞻性声明。无法保证本新闻稿中描述的在研或已批准产品将会在任何市场提交或批准销售，或用于任何额外适应症或标签，或在任何特定时间提交或批准，也无法保证此类产品在未来将会或将继续取得商业成功。

UCB is providing this information, including forward-looking statements, only as of the date of this press release and it does not reflect any potential impact from the evolving COVID-19 pandemic, unless indicated otherwise. UCB is following the worldwide developments diligently to assess the financial significance of this pandemic to UCB.

UCB仅在本新闻稿发布之日提供此信息，包括前瞻性声明，除非另有说明，否则该信息并未反映不断演变的COVID-19大流行可能带来的影响。UCB正在密切关注全球发展，以评估这场大流行对UCB的财务重要性。

UCB expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations. .

UCB明确表示，不对本新闻稿中包含的任何信息承担更新义务，无论是为了确认实际结果，还是为了报告或反映与其前瞻性声明相关的任何变化，或基于该声明的任何事件、条件或情况的变化，除非根据适用的法律法规要求进行更新。

Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction..

此外，本文件中包含的信息不构成出售或招揽购买任何证券的要约，也不得在任何未根据该司法管辖区的证券法进行注册或资格认证前，进行违法的证券要约、招揽或销售的任何司法管辖区中，进行证券的要约、招揽或销售。

References:

参考文献：

Barton M, et al. Phase II study of bepranemab in people with prodromal-mild Alzheimer’s disease: Population subgroup analysis. Presented at: AD/PD; 2025 April 1-5; Vienna, Austria.

巴顿 M 等。贝普拉单抗治疗前驱期至轻度阿尔茨海默病患者的二期研究：人群亚组分析。在2025年4月1日至5日于奥地利维也纳举行的AD/PD会议上展示。

Barton M, et al. Results from TOGETHER, a double-blind, placebo-controlled Phase II study evaluating efficacy, safety and tolerability of bepranemab in prodromal–mild AD. Presented at: 17th Clinical Trials on Alzheimer's Disease (CTAD); 2024 October 29 - November 1; Madrid, Spain.

巴顿·M 等。TOGETHER 研究结果，这是一项双盲、安慰剂对照的 II 期研究，评估了 bepranemab 在前驱至轻度阿尔茨海默病中的疗效、安全性和耐受性。报告于：第 17 届阿尔茨海默病临床试验（CTAD）；2024 年 10 月 29 日至 11 月 1 日；西班牙马德里。

Downey P, et al. A preclinical evaluation of UCB7853, an anti-alpha-synuclein antibody in clinical development for Parkinson’s disease. Presented at: AD/PD; 2025 April 1-5; Vienna, Austria.

Downey P 等。UCB7853 的临床前评估，这是一种正在帕金森病临床开发中的抗 α-突触核蛋白抗体。在 AD/PD 会议上发表；2025 年 4 月 1-5 日；奥地利维也纳。

Kremer P, et al. Phase I study results: UCB7853 safety, tolerability and pharmacokinetics in healthy participants (single-ascending dose) and people with Parkinson’s disease (multiple-ascending doses). Presented at: AD/PD; 2025 April 1-5; Vienna, Austria.

Kremer P, 等。一期研究结果：UCB7853 在健康参与者（单次递增剂量）和帕金森病患者（多次递增剂量）中的安全性、耐受性和药代动力学。报告于：AD/PD；2025年4月1-5日；奥地利维也纳。

Biagioni M, et al. Designing a patient-informed trial: ATLANTIS Phase II study of the D1 receptor PAM, UCB0022, in advanced Parkinson’s disease. Presented at: AD/PD; 2025 April 1-5; Vienna, Austria.

比亚焦尼 M 等。设计以患者为中心的试验：UCB0022（D1受体PAM）在晚期帕金森病中的ATLANTIS二期研究。报告于：AD/PD；2025年4月1-5日；奥地利维也纳。

https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/UCB7853

https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/UCB7853

. Accessed March 2025.

访问日期：2025年3月。

https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/UCB0022

https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/UCB0022

. Accessed March 2025.

访问时间：2025年3月。

Carson S, et al. Results from ORCHESTRA, a phase II proof-of-concept study assessing the efficacy and safety of minzasolmin in people with early-stage Parkinson’s disease. Presented at: AD/PD; 2025 April 1-5; Vienna, Austria.

Carson S 等。ORCHESTRA 二期概念验证研究结果，评估米扎索尔明在早期帕金森病患者中的疗效与安全性。报告于：AD/PD；2025年4月1日至5日；奥地利维也纳。

UCB Corporate Website.

UCB企业官网。

https://www.ucb.com/newsroom/press-releases/article/findings-from-minzasolmin-proof-of-concept-orchestra-study-shape-next-steps-in-ucb-parkinson-s-research-program

https://www.ucb.com/newsroom/press-releases/article/findings-from-minzasolmin-proof-of-concept-orchestra-study-shape-next-steps-in-ucb-parkinson-s-research-program

. Accessed March 2025.

访问日期：2025年3月。